Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

KIAA0930: A Cachexic Phenotype Inducer in Cancer Cells

News

July 26, 2023
PRESS RELEASE: On July 20, 2023, a new research paper was published in Oncotarget, entitled, “The uncharacterized transcript KIAA0930 confers a cachexic phenotype on cancer cells.” continue reading »

A Multiplex Assay to Assess Activated p300/CBP in Circulating Prostate Tumor Cells

News

July 24, 2023
PRESS RELEASE: On July 20, 2023, a new research paper was published in Oncotarget, entitled, “Development of a multiplex assay to assess activated p300/CBP in circulating prostate tumor cells.” continue reading »

Novel Therapeutic Strategy Against Melanoma: Combined Targeting of Hedgehog Signaling and BRD4

News

July 19, 2023
PRESS RELEASE: On May 26, 2023, a new editorial paper was published in Oncotarget, entitled, “Combined targeting of HEDGEHOG signaling and BRD4 as a novel therapeutic option against melanoma.” continue reading »

Case Report: Intrathoracic Synovial Sarcoma With BRAF V600E Mutation

News

July 18, 2023
PRESS RELEASE: On July 7, 2023, a new case report was published in Oncotarget, entitled, “Intrathoracic synovial sarcoma with BRAF V600E mutation.” continue reading »

Targeting Ras in Cancer Therapies: Advances in Protein Engineering

Oncotarget

July 14, 2023
In a new review, researchers from The Hebrew University of Jerusalem discuss the challenges associated with targeting Ras proteins and how protein engineering has emerged as a promising method to overcome these challenges. continue reading »